Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme
Author(s) -
Norbert Krug,
Jens M. Hohlfeld,
AnneMarie Kirsten,
Oliver Kornmann,
Kai Michael Beeh,
Dominik Kappeler,
Stephanie Korn,
Stanislav Ignatenko,
Wolfgang Timmer,
Cordelia Rogon,
Jana Zeitvogel,
Nan Zhang,
Joachim Bille,
Ursula Homburg,
Agnieszka Turowska,
Claus Bachert,
Thomas Werfel,
Roland Buhl,
Jonas Renz,
Holger Garn,
Harald Renz
Publication year - 2015
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1411776
Subject(s) - medicine , asthma , placebo , provocation test , immunology , allergen , eosinophil , eosinophilia , inhalation , fexofenadine , area under the curve , eosinophil cationic protein , gata3 , sputum , bronchoconstriction , allergy , pharmacology , anesthesia , pathology , tuberculosis , alternative medicine , biochemistry , chemistry , transcription factor , gene
The most prevalent phenotype of asthma is characterized by eosinophil-dominated inflammation that is driven by a type 2 helper T cell (Th2). Therapeutic targeting of GATA3, an important transcription factor of the Th2 pathway, may be beneficial. We evaluated the safety and efficacy of SB010, a novel DNA enzyme (DNAzyme) that is able to cleave and inactivate GATA3 messenger RNA (mRNA).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom